SQZ - SQZ STOCK NEWS

SQZ Biotechnologies reported its full-year 2020 results, highlighting significant milestones such as dosing its first patient and advancements across its pipeline. The company raised over $200 million in gross proceeds, ensuring financial stability through mid-2023 with cash reserves of $170.4 million. Revenue increased slightly to $21 million, while R&D expenses rose to $51.5 million, reflecting ongoing development efforts. However, the net loss widened to $50.6 million, indicating continued investment in growth despite challenges presented by COVID-19.

SQZ Biotechnologies (NYSE: SQZ) announced its participation in the AACR 2021 Annual Meeting, showcasing advanced data on its SQZ™ APC platform. The platform aims to enhance CD8+ T cell responses against cancers, specifically targeting KRAS mutations prevalent in a significant patient population. Presentations will cover the functionality of enhanced APCs (eAPCs) and their potential in treating various tumor types through innovative mRNA delivery. This research could expand treatment options for up to 100,000 KRAS-mutated cancer patients annually in the U.S.

SQZ Biotechnologies (NYSE:SQZ) announced that CEO Armon Sharei, PhD, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 am EST. The presentation will be accessible via the virtual conference portal, with individual meetings scheduled during the event. Replays of the webcast will be available for 90 days on the SQZ investors' website. SQZ Biotechnologies focuses on developing innovative cell therapies for cancer and other serious conditions, aiming to establish a new paradigm in cell therapy with rapid production timelines.

SQZ Biotechnologies Company (NYSE: SQZ) announced the pricing of its underwritten public offering of 3,000,000 shares of common stock at $20.00 per share. The offering also includes an option for underwriters to purchase up to 450,000 additional shares within 30 days. The offering is slated to close on February 17, 2021, subject to customary conditions. BofA Securities, Evercore ISI, and Stifel are acting as joint book-running managers. A registration statement for the offering was declared effective on February 11, 2021.

SQZ Biotechnologies Company (NYSE: SQZ) announced a public offering of 3,000,000 shares of common stock, with a potential additional 450,000 shares available through a 30-day underwriter option. The offering is subject to market conditions and no assurance can be made regarding its completion or terms. BofA Securities, Evercore ISI, and Stifel are the joint book-running managers, with BTIG as the lead manager. A registration statement has been filed with the SEC but is not yet effective, and the offering will proceed only through a prospectus.

SQZ Biotechnologies (NYSE: SQZ) announced that the FDA cleared its IND application for SQZ^TM Activating Antigen Carriers (SQZ AACs) targeting HPV+ tumors. The clinical trial, SQZ-AAC-HPV-101, aims to evaluate SQZ-AAC-HPV as a monotherapy and in combination with other immunotherapies. This is the first clinical program from SQZ's AAC platform. Preclinical studies showed robust immune responses and tumor reduction in mouse models. The trial will enroll HLA-A*02+ patients with various HPV16+ cancers, marking a significant milestone for SQZ's innovative cell therapy approach.

SQZ Biotechnologies (NYSE: SQZ) announced new preclinical data on its Tolerizing Antigen Carriers (SQZ TACs) presented by Shinu John, PhD, at the Antigen-Specific Immune Tolerance Digital Summit. SQZ TACs, a red blood cell-derived cell therapy, aims to induce immune tolerance to target antigens, showing promise for autoimmune diseases like type 1 diabetes and celiac disease. The data revealed that SQZ TACs could delete or inactivate antigen-specific CD4 and CD8 T cells while expanding regulatory T cells. Additionally, they protected diabetic mice, indicating significant therapeutic potential.

SQZ Biotechnologies (NYSE:SQZ) announced that CEO Armon Sharei will participate in a fireside chat at the Evercore ISI Virtual HealthCONx Conference on December 2, 2020, at 10:55 am EST. The event will be accessible via the "Events & Presentations" section on the SQZ website, with replays available for 90 days post-event. SQZ Biotech focuses on developing transformative cell therapies for cancer and other serious diseases, aiming to create well-tolerated treatments with accelerated production timelines and improved patient experiences.

SQZ Biotechnologies (NYSE: SQZ) announced participation in two upcoming virtual investor conferences. CEO Armon Sharei will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 1:20 pm EST, with a webcast available. The second event is the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 7:55 am EST/12:55 pm GMT, also featuring a webcast. SQZ focuses on developing innovative cell therapies for various diseases, aiming to improve patient experiences and outcomes.